Neurotrope (NASDAQ:NTRP) Trading 9.8% Higher

Neurotrope Inc (NASDAQ:NTRP)’s share price traded up 9.8% during mid-day trading on Wednesday . The company traded as high as $0.91 and last traded at $0.90, 1,033,943 shares were traded during mid-day trading. An increase of 592% from the average session volume of 149,466 shares. The stock had previously closed at $0.82.

A number of equities research analysts recently issued reports on the stock. Janney Montgomery Scott downgraded shares of Neurotrope from a “buy” rating to a “neutral” rating and lowered their target price for the company from $13.00 to $1.00 in a report on Wednesday, September 11th. Zacks Investment Research upgraded shares of Neurotrope from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a report on Wednesday, August 21st. ValuEngine upgraded shares of Neurotrope from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Maxim Group downgraded shares of Neurotrope from a “buy” rating to a “hold” rating in a report on Monday, September 9th.

The firm’s 50 day simple moving average is $4.56 and its 200-day simple moving average is $5.79. The company has a market capitalization of $10.81 million, a PE ratio of -0.66 and a beta of 2.40.



Neurotrope (NASDAQ:NTRP) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.07. On average, sell-side analysts predict that Neurotrope Inc will post -1.33 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTRP. MYDA Advisors LLC purchased a new stake in Neurotrope during the first quarter worth approximately $690,000. Vanguard Group Inc. grew its stake in Neurotrope by 21.7% during the second quarter. Vanguard Group Inc. now owns 266,735 shares of the company’s stock worth $2,139,000 after buying an additional 47,609 shares during the period. BlackRock Inc. grew its stake in Neurotrope by 144.3% during the second quarter. BlackRock Inc. now owns 60,041 shares of the company’s stock worth $482,000 after buying an additional 35,464 shares during the period. NorthRock Partners LLC grew its stake in Neurotrope by 45.5% during the second quarter. NorthRock Partners LLC now owns 104,000 shares of the company’s stock worth $834,000 after buying an additional 32,500 shares during the period. Finally, Cannell Peter B & Co. Inc. grew its stake in Neurotrope by 7.5% during the second quarter. Cannell Peter B & Co. Inc. now owns 229,481 shares of the company’s stock worth $1,840,000 after buying an additional 16,100 shares during the period. Institutional investors own 15.00% of the company’s stock.

Neurotrope Company Profile (NASDAQ:NTRP)

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.

Read More: Limitations to arbitrage trading

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.